<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225197</url>
  </required_header>
  <id_info>
    <org_study_id>CK Perioptic-01</org_study_id>
    <nct_id>NCT02225197</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors</brief_title>
  <official_title>A Phase II Study of Fractionated CyberKnife Stereotactic Radiosurgery to Perioptic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Community Cancer Center, Normal, Illinois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Community Cancer Center, Normal, Illinois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects (good and bad) CyberKnife stereotactic
      radiosurgery has on tumors near the critical structures of the eye (optic apparatus).

      The investigators hypothesize that hypofractionated stereotactic radiotherapy via the
      CyberKnife Â® can deliver tumor ablating doses of radiation to perioptic lesions safely and
      effectively while sparing the adjacent optic apparatus and normal brain tissues from
      receiving damaging doses of radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CyberKnife system is a type of radiation machine that uses a special system to precisely
      focus large doses of x-rays (radiation) on the tumor. The device is designed to concentrate
      large doses of radiation onto the tumor so that injury from radiation to the nearby normal
      tissue will be minimal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the local control rate of patients with perioptic lesions treated with stereotactic CyberKnife radiosurgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the acute adverse and delayed effects of this regimen on the optic apparatus</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Tumor, Benign, Optic Nerve</condition>
  <arm_group>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Radiosurgery</intervention_name>
    <description>25 Gy delivered in 5 fractions of 5 Gy per fraction</description>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
    <other_name>CyberKnife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Perioptic lesion within 2mm of the optic apparatus

          -  Age &gt;= 21

          -  KPS &gt;= 50

          -  Planning Target Volume (PTV) &lt;= 6.0 cm in maximal diameter

        Exclusion Criteria:

          -  Malignant histology

          -  Age &lt; 21

          -  KPS &lt;= 40

          -  Planning Target Volume (PTV) &gt; 6.0 cm in maximal diameter

          -  Prior whole brain XRT

          -  Gross total resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shermian Woodhouse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perioptic</keyword>
  <keyword>Stereotactic</keyword>
  <keyword>Radiation</keyword>
  <keyword>Benign brain tumor</keyword>
  <keyword>Optic apparatus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

